Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Operations (2016 - 2025)

Wave Life Sciences' Cash from Operations history spans 11 years, with the latest figure at 33776000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 22.62% year-over-year to 33776000.0; the TTM value through Dec 2025 reached 187493000.0, down 24.15%, while the annual FY2025 figure was 187493000.0, 24.15% down from the prior year.
  • Cash from Operations reached 33776000.0 in Q4 2025 per WVE's latest filing, up from 44666000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 85522000.0 in Q1 2023 to a low of 63039000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 28736200.0, with a median of 33608000.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: plummeted 375.47% in 2022, then skyrocketed 314.49% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 7033000.0 in 2021, then plummeted by 375.47% to 33440000.0 in 2022, then grew by 0.6% to 33239000.0 in 2023, then tumbled by 31.32% to 43648000.0 in 2024, then grew by 22.62% to 33776000.0 in 2025.
  • Per Business Quant, the three most recent readings for WVE's Cash from Operations are 33776000.0 (Q4 2025), 44666000.0 (Q3 2025), and 46012000.0 (Q2 2025).